Search hospitals > Wisconsin > Berlin
ThedaCare Cancer Care - Berlin
Claim this profileBerlin, Wisconsin 54923
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
12 reported clinical trials
4 medical researchers
Summary
ThedaCare Cancer Care - Berlin is a medical facility located in Berlin, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer and other specialties. ThedaCare Cancer Care - Berlin is involved with conducting 12 clinical trials across 51 conditions. There are 4 research doctors associated with this hospital, such as Matthias Weiss, Natasha C. Edwin, Shannon Schmidt, and Charissa K. Williams.Area of expertise
1Cancer
Stage IV
Stage III
Stage I
2Breast Cancer
HER2 positive
Stage II
HER2 negative
Top PIs
Matthias WeissThedaCare Regional Cancer Center5 years of reported clinical research
Expert in Cancer
Studies Tumors
40 reported clinical trials
73 drugs studied
Natasha C. EdwinThedaCare Regional Cancer Center5 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
8 reported clinical trials
17 drugs studied
Shannon SchmidtThedaCare Regional Cancer Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
6 reported clinical trials
18 drugs studied
Charissa K. WilliamsThedaCare Cancer Care - Shawano1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
1 reported clinical trial
1 drug studied
Clinical Trials running at ThedaCare Cancer Care - Berlin
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Colon Cancer
Colorectal Cancer
Solid Tumors
Tumors
Recurrence
Ovarian Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Online Sexual Health Program
for Breast Cancer Survivors
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns. This study is being done to find out if the study approach is better or worse than the usual approach to helping breast cancer survivors manage cancer-related sexual concerns. The usual approach is defined as care most cancer survivors get for their cancer-related sexual concerns. Participants will complete a questionnaire and if they qualify, they will be assigned to one of sixteen groups of participants. Groups will get access to various kinds of help through an Internet-delivered program called SHINE, which was designed and is run by researchers at the University of Virginia Center for Behavioral Health and Technology. All groups will get access to education about sexual health after cancer: either a standard education website or an enhanced education web program. Groups may also receive up to three additional web programs on: talking to your clinicians about sexual concerns, and/or talking to your partner about sexual concerns, and/or increasing intimacy. Participants are asked to complete the SHINE program within 12 weeks. After participants finish this 12-week period, the study team will ask them to complete a questionnaire to check in with the participant. The participant will be asked one additional time 12 weeks later to complete another questionnaire to see how the participant is doing. A participant will be in the study for 24 weeks.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at ThedaCare Cancer Care - Berlin?
ThedaCare Cancer Care - Berlin is a medical facility located in Berlin, Wisconsin. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer and other specialties. ThedaCare Cancer Care - Berlin is involved with conducting 12 clinical trials across 51 conditions. There are 4 research doctors associated with this hospital, such as Matthias Weiss, Natasha C. Edwin, Shannon Schmidt, and Charissa K. Williams.